INDV Stock Analysis: Indivior Ordinary Shares | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 4.882m USD | 12M Return: 157.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 67.5M
Qual. Beats: 5
Rev. Trend: 93.0%
Qual. Beats: 6
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing buprenorphine-based prescription medicines for the treatment of opioid use disorder (OUD) and related substance use conditions, with operations spanning the United States, Europe, Canada, Australia, and other international markets. The company operates within the GICS Biotechnology sub-industry of the Health Care sector, addressing the medication-assisted treatment (MAT) segment of the addiction therapeutics market.
Its commercial portfolio is anchored by SUBLOCADE, a once-monthly extended-release buprenorphine injection, and SUBOXONE Film, a sublingual buprenorphine/naloxone combination product. The company also markets legacy formulations including SUBOXONE Tablet and SUBUTEX Tablet, which have historically played a central role in OUD treatment protocols.
Indiviors development pipeline includes INDV-2000, a selective orexin-1 receptor antagonist currently in Phase 2 clinical trials for moderate to severe OUD, and INDV-6001, a long-acting injectable buprenorphine candidate being advanced in collaboration with Alar Pharmaceuticals. The company is headquartered in North Chesterfield, Virginia, and was originally incorporated in 2014 as Indivior PLC, having recently adopted its current corporate name in January 2026.
- SUBLOCADE sales accelerate as opioid treatment demand grows
- SUBOXONE Film generic competition pressures pricing and margins
- Phase 2 INDV-2000 data readout drives pipeline valuation
| Net Income: 251.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -24.97 > 1.0 |
| NWC/Revenue: -8.68% < 20% (prev -10.42%; Δ 1.74% < -1%) |
| CFO/TA -0.09 > 3% & CFO -103.0m > Net Income 251.0m |
| Net Debt (357.0m) to EBITDA (352.0m): 1.01 < 3 |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (129.0m) vs 12m ago 4.30% < -2% |
| Gross Margin: 83.11% > 18% (prev 81.64%; Δ 1.47% > 0.5%) |
| Asset Turnover: 100.4% > 50% (prev 85.16%; Δ 15.23% > 0%) |
| Interest Coverage Ratio: 8.38 > 6 (EBIT TTM 335.0m / Interest Expense TTM 40.0m) |
| A: -0.09 (Total Current Assets 667.0m - Total Current Liabilities 779.0m) / Total Assets 1.20b |
| B: -0.23 (Retained Earnings -280.0m / Total Assets 1.20b) |
| C: 0.26 (EBIT TTM 335.0m / Avg Total Assets 1.29b) |
| D: -0.11 (Book Value of Equity -144.0m / Total Liabilities 1.34b) |
| Altman-Z'' = 0.26 = B |
| DSRI: 1.06 (Receivables 285.0m/243.0m, Revenue 1.29b/1.17b) |
| GMI: 0.98 (GM 81.64% / 83.11%) |
| AQI: 1.15 (AQ_t 0.29 / AQ_t-1 0.26) |
| SGI: 1.10 (Revenue 1.29b / 1.17b) |
| TATA: 0.30 (NI 251.0m - CFO -103.0m) / TA 1.20b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 40.21 with a total of 1,234,481 shares traded. Over the past week, the price has changed by +0.55%, over one month by +4.71%, over three months by +27.25% and over the past year by +157.43%.
Current recommended Stop Loss: 37.10 (which is 7.7% or 2.2 ATR below the current price).
Indivior Ordinary Shares has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy INDV.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.8 | 26.4% |
P/E Trailing = 20.9645
P/E Forward = 13.3869
P/S = 3.7844
P/B = 145.2492
Revenue TTM = 1.29b USD
EBIT TTM = 335.0m USD
EBITDA TTM = 352.0m USD
Long Term Debt = 486.0m USD (from longTermDebt, last quarter)
Short Term Debt = 9.00m USD (from shortTermDebt, last quarter)
Debt = 532.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 23.0m
Net Debt = 357.0m USD (calculated: Debt 532.0m - CCE 175.0m)
Enterprise Value = 5.24b USD (4.88b + Debt 532.0m - CCE 175.0m)
Interest Coverage Ratio = 8.38 (Ebit TTM 335.0m / Interest Expense TTM 40.0m)
EV/FCF = -28.38x (Enterprise Value 5.24b / FCF TTM -184.6m)
FCF Yield = -3.52% (FCF TTM -184.6m / Enterprise Value 5.24b)
FCF Margin = -14.30% (FCF TTM -184.6m / Revenue TTM 1.29b)
Net Margin = 19.44% (Net Income TTM 251.0m / Revenue TTM 1.29b)
Gross Margin = 83.11% ((Revenue TTM 1.29b - Cost of Revenue TTM 218.0m) / Revenue TTM)
Gross Margin QoQ = 87.38% (prev 82.12%)
Tobins Q-Ratio = 4.38 (Enterprise Value 5.24b / Total Assets 1.20b)
Interest Expense / Debt = 7.52% (Interest Expense 40.0m / Debt 532.0m)
Taxrate = 14.92% (44.0m / 295.0m)
NOPAT = 285.0m (EBIT 335.0m * (1 - 14.92%))
Current Ratio = 0.86 (Total Current Assets 667.0m / Total Current Liabilities 779.0m)
Debt / Equity = -3.69 (negative equity) (Debt 532.0m / totalStockholderEquity, last quarter -144.0m)
Debt / EBITDA = 1.01 (Net Debt 357.0m / EBITDA 352.0m)
Debt / FCF = -1.93 (negative FCF - burning cash) (Net Debt 357.0m / FCF TTM -184.6m)
Total Stockholder Equity = -176.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.52% (Net Income 251.0m / Total Assets 1.20b)
RoE = -142.0% (negative equity) (Net Income TTM 251.0m / Total Stockholder Equity -176.8m)
RoCE = 108.3% (EBIT 335.0m / Capital Employed (Equity -176.8m + L.T.Debt 486.0m))
RoIC = 78.64% (NOPAT 285.0m / Invested Capital 362.5m)
WACC = 7.44% (E(4.88b)/V(5.41b) * Re(7.55%) + D(532.0m)/V(5.41b) * Rd(7.52%) * (1-Tc(0.15)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -80.05 | Cagr: -4.16%
[DCF] Fair Price = unknown (Cash Flow -184.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.58 | # QB: 5
Revenue Correlation: 93.04 | Revenue CAGR: 7.50% | SUE: 1.77 | # QB: 6
EPS current Quarter (2026-06-30): EPS=0.91 | Chg30d=-1.43% | Revisions=+40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.97 | Chg30d=-1.94% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=3.82 | Chg30d=-0.72% | Revisions=+57% | GrowthEPS=+53.0% | GrowthRev=+1.5%
EPS next Year (2027-12-31): EPS=4.14 | Chg30d=+5.67% | Revisions=+57% | GrowthEPS=+8.3% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +67% (up=11, down=1)